Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

Schedule of Financial Instrument Measured On Recurring Basis

					Fair Value Measurements
	As of December 31, 2023				As of December 31, 2023
	Carrying Amount		Fair Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen (1)	$	453	$	453	$	-	$	-	$	453
Note payable:
BroadOak loan		10,000		9,343		-		-		9,343
	$	10,453	$	9,796	$	-	$	-	$	9,796

					Fair Value Measurements
	As of December 31, 2022				As of December 31, 2022
	Carrying Amount		Fair Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen (1)	$	1,088	$	1,088	$	-	$	-	$	1,088
Note payable:
BroadOak loan		10,000		11,165		-		-		11,165
	$	11,088	$	12,253	$	-	$	-	$	12,253

(1)(2) See Note 10, Accrued Expenses and Other Long-Term Liabilities

Schedule of Fair Value, Assets Measured On Recurring Basis, Unobservable Input Reconciliation

											Adjustment
	December 31, 2022		Payments			Transferred to Accrued Expenses			Accretion/ Interest Accrued		to Fair Value/ Mark to Market		December 31, 2023
Asuragen	$	1,088	$	-		$	(754	)	$	112	$	7	$	453
BroadOak loan		11,165		(2,500	)		-			-		678		9,343
	$	12,253	$	(2,500	)	$	(754	)	$	112	$	685	$	9,796